BioAffinity Technologies shares rose 54.78% to $10.20 Wednesday after the company said it was positioning CyPath Lung for post-curative surveillance of lung cancer patients. The stock had climbed more than 65% in Tuesday premarket trading, with volume exceeding 17 million shares, roughly triple its three-month average daily turnover of 5.91 million shares. CyPath Lung is intended to help physicians assess new pulmonary nodules that appear after treatment and distinguish possible malignancy from benign or treatment-related changes. The expansion follows an Aug. 18 nationwide federal healthcare distribution agreement with AvMEDICAL covering Veterans Affairs hospitals and military medical systems. BioAffinity reported a 216% year-over-year increase in CyPath Lung test volume and a 122% rise in ordering physician offices in its Aug. 7 second-quarter update. A 1-for-15 reverse split reduced outstanding common stock to approximately 592,373 shares to maintain Nasdaq listing compliance, leaving a low float that can amplify price swings. The company cites more than 680,000 Americans living with a past lung cancer diagnosis as of Jan. 1, 2025, and a National Cancer Institute projection of roughly 230,000 new cases in 2026. CyPath Lung is marketed as a Laboratory Developed Test that complements, rather than replaces, other clinical findings. Existing risks include cash depletion, declining revenue and potential Nasdaq delisting.